Antigen recognition by CD1d-restricted NKT T cell receptors

Seminars in Immunology

Volumn 22, Issue 2, 2010, Pages 61-67

  Godfrey, Dale I ^a   Pellicci, Daniel G ^a   Patel, Onisha ^b   Kjer Nielsen, Lars ^a   McCluskey, James ^a   Rossjohn, Jamie ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Australian Government Australian Research Council   (Australia)

Author keywords

CD1d; Glycolipids; NKT cells; T cell receptor

Indexed keywords

CD1D ANTIGEN; GLYCOLIPID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NATURAL KILLER CELL RECEPTOR; PEPTIDE; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; AUTOIMMUNITY; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LINEAGE; CELL MATURATION; HUMAN; IMMUNE SYSTEM; MOLECULAR DOCKING; MOLECULAR INTERACTION; NATURAL KILLER CELL; NONHUMAN; REVIEW;

ANIMALS; ANTIGENS; ANTIGENS, CD1D; HUMANS; IMMUNITY, INNATE; LIPIDS; NATURAL KILLER T-CELLS; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; T-CELL ANTIGEN RECEPTOR SPECIFICITY;

EID: 77949271519     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2009.10.004     Document Type: Review

References (71)

1. Godfrey D.I., MacDonald H.R., Kronenberg M., Smyth M.J., and Van Kaer L. NKT cells: what's in a name?. Nat Rev Immunol 4 (2004) 231-237
2. Terabe M., and Berzofsky J.A. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol 28 (2007) 491-496
3. Cardell S., Tangri S., Chan S., Kronenberg M., Benoist C., and Mathis D. CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice. J Exp Med 182 (1995) 993-1004
4. Park S.H., Weiss A., Benlagha K., Kyin T., Teyton L., and Bendelac A. The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families. J Exp Med 193 (2001) 893-904
5. Moody D.B., Zajonc D.M., and Wilson I.A. Anatomy of CD1-lipid antigen complexes. Nat Rev Immunol 5 (2005) 387-399
6. Gadola S.D., Zaccai N.R., Harlos K., Shepherd D., Castro-Palomino J.C., Ritter G., et al. Structure of human CD1b with bound ligands at 2.3 A, a maze for alkyl chains. Nat Immunol 3 (2002) 721-726
7. Zajonc D.M., Elsliger M.A., Teyton L., and Wilson I.A. Crystal structure of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 A. Nat Immunol 4 (2003) 808-815
8. Zeng Z., Castano A.R., Segelke B.W., Stura E.A., Peterson P.A., and Wilson I.A. Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove. Science 277 (1997) 339-345
9. Barral D.C., and Brenner M.B. CD1 antigen presentation: how it works. Nat Rev Immunol 7 (2007) 929-941
10. Miyamoto K., Miyake S., and Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing T(H)2 bias of natural killer T cells. Nature 413 (2001) 531-534
11. Yu K.O., Im J.S., Molano A., Dutronc Y., Illarionov P.A., Forestier C., et al. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of {alpha}-galactosylceramides. Proc Natl Acad Sci USA 102 (2005) 3383-3388
12. Schmieg J., Yang G., Franck R.W., and Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-galactosylceramide. J Exp Med 198 (2003) 1631-1641
13. Kinjo Y., Wu D., Kim G., Xing G.W., Poles M.A., Ho D.D., et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434 (2005) 520-525
14. Mattner J., Debord K.L., Ismail N., Goff R.D., Cantu III C., Zhou D., et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434 (2005) 525-529
15. Sriram V., Du W., Gervay-Hague J., and Brutkiewicz R.R. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur J Immunol 35 (2005) 1692-1701
16. Kinjo Y., Tupin E., Wu D., Fujio M., Garcia-Navarro R., Benhnia M.R., et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol 7 (2006) 978-986
17. Zhou D., Mattner J., Cantu III C., Schrantz N., Yin N., Gao Y., et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 306 (2004) 1786-1789
18. Ortaldo J.R., Young H.A., Winkler-Pickett R.T., Bere Jr. E.W., Murphy W.J., and Wiltrout R.H. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J Immunol 172 (2004) 943-953
19. Parekh V.V., Singh A.K., Wilson M.T., Olivares-Villagomez D., Bezbradica J.S., Inazawa H., et al. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids. J Immunol 173 (2004) 3693-3706
20. Wu D.Y., Segal N.H., Sidobre S., Kronenberg M., and Chapman P.B. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med 198 (2003) 173-181
21. Ambrosino E., Terabe M., Halder R.C., Peng J., Takaku S., Miyake S., et al. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol 179 (2007) 5126-5136
22. Halder R.C., Aguilera C., Maricic I., and Kumar V. Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest 117 (2007) 2302-2312
23. Jahng A., Maricic I., Aguilera C., Cardell S., Halder R.C., and Kumar V. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med 199 (2004) 947-957
24. Chang D.H., Deng H., Matthews P., Krasovsky J., Ragupathi G., Spisek R., et al. Inflammation associated lysophospholipids as ligands for CD1d restricted T cells in human cancer. Blood 112 (2008) 1308-1316
25. Van Rhijn I., Young D.C., Im J.S., Levery S.B., Illarionov P.A., Besra G.S., et al. CD1d-restricted T cell activation by nonlipidic small molecules. Proc Natl Acad Sci USA 101 (2004) 13578-13583
26. Godfrey D.I., and Berzins S.P. Control points in NKT-cell development. Nat Rev Immunol 7 (2007) 505-518
27. Starr T.K., Jameson S.C., and Hogquist K.A. Positive and negative selection of T cells. Annu Rev Immunol 21 (2003) 139-176
28. Kronenberg M., and Engel I. On the road: progress in finding the unique pathway of invariant NKT cell differentiation. Curr Opin Immunol 19 (2007) 186-193
29. Benlagha K., Wei D.G., Veiga J., Teyton L., and Bendelac A. Characterization of the early stages of thymic NKT cell development. J Exp Med 202 (2005) 485-492
30. Jordan M.A., Fletcher J.M., Pellicci D., and Baxter A.G. Slamf1, the NKT cell control gene Nkt1. J Immunol 178 (2007) 1618-1627
31. Griewank K., Borowski C., Rietdijk S., Wang N., Julien A., Wei D.G., et al. Homotypic interactions mediated by slamf1 and slamf6 receptors control NKT cell lineage development. Immunity 27 (2007) 751-762
32. Borowski C., and Bendelac A. Signaling for NKT cell development: the SAP-FynT connection. J Exp Med 201 (2005) 833-836
33. McNab F.W., Berzins S.P., Pellicci D.G., Kyparissoudis K., Field K., Smyth M.J., et al. The influence of CD1d in postselection NKT cell maturation and homeostasis. J Immunol 175 (2005) 3762-3768
34. Lantz O., and Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med 180 (1994) 1097-1106
35. Shimamura M., Ohteki T., Beutner U., and MacDonald H.R. Lack of directed V alpha 14-J alpha 281 rearrangements in NK1+ T cells. Eur J Immunol 27 (1997) 1576-1579
36. Gadola S.D., Silk J.D., Jeans A., Illarionov P.A., Salio M., Besra G.S., et al. Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases. J Exp Med 203 (2006) 2293-2303
37. Schumann J., Facciotti F., Panza L., Michieletti M., Compostella F., Collmann A., et al. Differential alteration of lipid antigen presentation to NKT cells due to imbalances in lipid metabolism. Eur J Immunol 37 (2007) 1431-1441
38. Chiu Y.H., Park S.H., Benlagha K., Forestier C., Jayawardena-Wolf J., Savage P.B., et al. Multiple defects in antigen presentation and T cell development by mice expressing cytoplasmic tail-truncated CD1d. Nat Immunol 3 (2002) 55-60
39. Li Y., Thapa P., Hawke D., Kondo Y., Furukawa K., Furukawa K., et al. Immunologic glycosphingolipidomics and NKT cell development in mouse thymus. J Proteome Res 8 (2009) 2740-2751
40. Porubsky S., Speak A.O., Luckow B., Cerundolo V., Platt F.M., and Grone H.J. Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc Natl Acad Sci USA 104 (2007) 5977-5982
41. Christiansen D., Milland J., Mouhtouris E., Vaughan H., Pellicci D.G., McConville M.J., et al. Humans lack iGb3 due to the absence of functional iGb3-synthase: implications for NKT cell development and transplantation. PLoS Biol 6 (2008) e172
42. Speak A.O., Salio M., Neville D.C., Fontaine J., Priestman D.A., Platt N., et al. Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc Natl Acad Sci USA (2007)
43. Martin E., Treiner E., Duban L., Guerri L., Laude H., Toly C., et al. Stepwise development of MAIT cells in mouse and human. PLoS Biol 7 (2009) e54
44. Treiner E., and Lantz O. CD1d- and MR1-restricted invariant T cells: of mice and men. Curr Opin Immunol 18 (2006) 519-526
45. Brigl M., and Brenner M.B. CD1: antigen presentation and T cell function. Annu Rev Immunol 22 (2004) 817-890
46. Li W., Kim M.G., Gourley T.S., McCarthy B.P., Sant'Angelo D.B., and Chang C.H. An alternate pathway for CD4 T cell development: thymocyte-expressed MHC class II selects a distinct T cell population. Immunity 23 (2005) 375-386
47. Li W., Sofi M.H., Rietdijk S., Wang N., Terhorst C., and Chang C.H. The SLAM-associated protein signaling pathway is required for development of CD4(+) T cells selected by homotypic thymocyte interaction. Immunity 27 (2007) 763-774
48. Kjer-Nielsen L., Borg N.A., Pellicci D.G., Beddoe T., Kostenko L., Clements C.S., et al. A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d/glycolipid recognition. J Exp Med 203 (2006) 661-673
49. Gadola S.D., Koch M., Marles-Wright J., Lissin N.M., Shepherd D., Matulis G., et al. Structure and binding kinetics of three different human CD1d-{alpha}-galactosylceramide-specific T cell receptors. J Exp Med 203 (2006) 699-710
50. Borg N.A., Wun K.S., Kjer-Nielsen L., Wilce M.C., Pellicci D.G., Koh R., et al. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448 (2007) 44-49
51. Pellicci D.G., Patel O., Kjer-Nielsen L., Pang S.S., Sullivan L.C., Kyparissoudis K., et al. Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. Immunity 31 (2009) 47-59
52. Godfrey D.I., Rossjohn J., and McCluskey J. The fidelity, occasional promiscuity, and versatility of T cell receptor recognition. Immunity 28 (2008) 304-314
53. Tynan F.E., Burrows S.R., Buckle A.M., Clements C.S., Borg N.A., Miles J.J., et al. T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide. Nat Immunol 6 (2005) 1114-1122
54. Pyz E., Naidenko O., Miyake S., Yamamura T., Berberich I., Cardell S., et al. The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR. J Immunol 176 (2006) 7447-7455
55. Cui J.Q., Shin T., Kawano T., Sato H., Kondo E., Toura I., et al. Requirement for V(Alpha)14 Nkt cells in Il-12-mediated rejection of tumors. Science 278 (1997) 1623-1626
56. Mallevaey T., Scott-Browne J.P., Matsuda J.L., Young M.H., Pellicci D.G., Patel O., et al. T cell receptor CDR2 beta and CDR3 beta loops collaborate functionally to shape the iNKT cell repertoire. Immunity 31 (2009) 60-71
57. Scott-Browne J.P., Matsuda J.L., Mallevaey T., White J., Borg N.A., McCluskey J., et al. Germline-encoded recognition of diverse glycolipids by natural killer T cells. Nat Immunol 8 (2007) 1105-1113
58. Wun K.S., Borg N.A., Kjer-Nielsen L., Beddoe T., Koh R., Richardson S.K., et al. A minimal binding footprint on CD1d-glycolipid is a basis for selection of the unique human NKT TCR. J Exp Med 205 (2008) 939-949
59. Godfrey D.I., McCluskey J., and Rossjohn J. CD1d antigen presentation: treats for NKT cells. Nat Immunol 6 (2005) 754-756
60. Borg N.A., Kjer-Nielsen L., McCluskey J., and Rossjohn J. Structural insight into natural killer T cell receptor recognition of CD1d. Adv Exp Med Biol 598 (2007) 20-34
61. Zajonc D.M., Savage P.B., Bendelac A., Wilson I.A., and Teyton L. Crystal structures of mouse CD1d-iGb3 complex and its cognate Valpha14 T cell receptor suggest a model for dual recognition of foreign and self glycolipids. J Mol Biol 377 (2008) 1104-1116
62. Schumann J., Mycko M.P., Dellabona P., Casorati G., and Macdonald H.R. Cutting edge: influence of the TCR Vbeta domain on the selection of semi-invariant NKT cells by endogenous ligands. J Immunol 176 (2006) 2064-2068
63. Wei D.G., Curran S.A., Savage P.B., Teyton L., and Bendelac A. Mechanisms imposing the V{beta} bias of V{alpha}14 natural killer T cells and consequences for microbial glycolipid recognition. J Exp Med 203 (2006) 1197-1207
64. Archbold J.K., Macdonald W.A., Gras S., Ely L.K., Miles J.J., Bell M.J., et al. Natural micropolymorphism in human leukocyte antigens provides a basis for genetic control of antigen recognition. J Exp Med 206 (2009) 209-219
65. Tynan F.E., Reid H.H., Kjer-Nielsen L., Miles J.J., Wilce M.C., Kostenko L., et al. A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule. Nat Immunol 8 (2007) 268-276
66. Koch M., Stronge V.S., Shepherd D., Gadola S.D., Mathew B., Ritter G., et al. The crystal structure of human CD1d with and without alpha-galactosylceramide. Nat Immunol 6 (2005) 819-826
67. Zajonc D.M., Cantu III C., Mattner J., Zhou D., Savage P.B., Bendelac A., et al. Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat Immunol 6 (2005) 810-818
68. Zajonc D.M., Maricic I., Wu D., Halder R., Roy K., Wong C.H., et al. Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J Exp Med 202 (2005) 1517-1526
69. Wu D., Zajonc D.M., Fujio M., Sullivan B.A., Kinjo Y., Kronenberg M., et al. Design of natural killer T cell activators: structure and function of a microbial glycosphingolipid bound to mouse CD1d. Proc Natl Acad Sci USA 103 (2006) 3972-3977
70. Zajonc D.M., Ainge G.D., Painter G.F., Severn W.B., and Wilson I.A. Structural characterization of mycobacterial phosphatidylinositol mannoside binding to mouse CD1d. J Immunol 177 (2006) 4577-4583
71. Giabbai B., Sidobre S., Crispin M.D., Sanchez-Ruiz Y., Bachi A., Kronenberg M., et al. Crystal structure of mouse CD1d bound to the self ligand phosphatidylcholine: a molecular basis for NKT cell activation. J Immunol 175 (2005) 977-984